Business
Shield to Present at Baird Healthcare Conference
Shield to Present at Baird Healthcare Conference.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 3693P Shield Therapeutics PLC 31 August 2017 \n\n\nShield Therapeutics plc to Present at the Baird Global Healthcare Conference on Wednesday, September 6, 2017\nLondon, UK, 31 August 2017: Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, today announced that Carl Sterritt, Chief Executive Officer, will present at the Baird Global Healthcare Conference on Wednesday, September 6, 2017 at 9:05 AM ET in New York. Mr. Sterritt will give a corporate overview, review the Company's late-stage and commercial product portfolio, and provide an update on upcoming milestones, including key clinical trial readouts and potential subsequent regulatory submission.\n \nAn audio webcast of the presentation will be available in the events section of the Company's website, or by clicking here. A replay will be available for a limited time following the presentation.\n \nAbout Shield Therapeutics\nShield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals, which address areas of unmet medical need. The Group has a marketed product, Feraccru®, for the treatment of IDA in adult patients with IBD which has exclusive IP rights until the mid-2030's. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com.\nFor further information please contact:\n \nShield Therapeutics plc +44 (0) 207 186 8500 \nJoanne Estell, Chief Financial Officer\nKarl Keegan, Corporate Development Director\n \nNominated Adviser and Joint Broker  ...